Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00173225 |
The aims of this study are to investigate the association between sputum and plasma levels of nociceptin and substance P with cough severity and airway hyperreactivity in patients with asthma, COPD and chronic cough.
Condition |
---|
Asthma COPD Cough |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Defined Population, Prospective Study |
Official Title: | Association Between Sputum and Plasma Levels of Nociceptin and Substance P With Cough Severity and Airway Hyperreactivity in Patients With Asthma, COPD and Chronic Cough |
Estimated Enrollment: | 300 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | June 2005 |
Recent animal studies have found that nociceptin can inhibit cough responses induced by capsaicin. We hypothesize that sputum and plasma levels of these peptides may reflect some neurochemical alterations in airway cough reflex or neurogenic inflammation in asthma or COPD. The aims of this study are to investigate the association between sputum and plasma levels of nociceptin and substance P with cough severity and airway hyperreactivity in patients with asthma, COPD and chronic cough. We will enroll 260 patients (100 patients with asthma, 60 with COPD and 100 with chronic cough) as well as 40 healthy subjects for this study. Sputum and peripheral blood will be collected and concentrations of nociceptin and substance P will be measured by ELISA. These levels will be correlated with cough severity (symptom scores), and airway hyperresponsiveness to inhaled methacholine as measured by PC20. Sputum and plasma concentrations of both peptides will be rechecked after clinical improvements in cough or airway symptoms are achieved after therapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:patients with asthma, COPD, chronic cough
-
Exclusion Criteria:patients refusing blood sampling
Contact: Ping-Hung Kuo, MD | 886-2-23123456 ext 3075 | kph@ntumc.org |
Taiwan | |
Ping-Hung Kuo | Recruiting |
Taipei, Taiwan, 100 | |
Contact: Ping-Hung Kuo, MD 886-2-23123456 ext 3075 kph@ntumc.org | |
Principal Investigator: Ping-Hung Kuo, MD |
Principal Investigator: | Ping-Hung Kuo, MD | Department of Internal Medicine, National Taiwan University Hospital |
Study ID Numbers: | 9461700531 |
Study First Received: | September 12, 2005 |
Last Updated: | September 12, 2005 |
ClinicalTrials.gov Identifier: | NCT00173225 |
Health Authority: | Taiwan: Department of Health |
nociceptin sunstance P asthma COPD cough |
Respiration Disorders Nociceptin Asthma Cough Substance P Signs and Symptoms Lung Diseases, Obstructive |
Hypersensitivity Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate Signs and Symptoms, Respiratory Pulmonary Disease, Chronic Obstructive Respiratory Hypersensitivity |
Vasodilator Agents Immune System Diseases Bronchial Diseases |
Therapeutic Uses Cardiovascular Agents Pharmacologic Actions |